AdAlta Company Description

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia.

Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration.

It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University.

The company was incorporated in 2006 and is based in Camberwell, Australia.

AdAlta Limited

Country	Australia
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	1
CEO	Timothy Oldham

Contact Details

Address: 697 Burke Road Camberwell, VIC 3124 Australia
Phone	61 3 9479 5159
Website	adalta.com.au

Stock Details

Ticker Symbol	1AD
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000001AD2
SIC Code	2836

Key Executives

Name	Position
Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.	Chief Executive Officer, MD and Director
Angus Tester Ph.D.	Senior Director of Operations
Prof. Michael Foley Ph.D.	Founding Chief Scientist
Dr. Andrew Peter O'Brien MBA., Ph.D.	Head of Corporate Development
Janette Dixon	Head of Business Development
Dr. Kevin Patrick Lynch FFPM, M.D., MBBS	Consultant Chief Medical Officer of Oncology
Cameron Peter Jones C.A.	Company Secretary